Researchers sequencing healthy liver tissue from children treated for liver cancer found an average of about 2,200 mutations per sample, a burden more typical of a middle-aged adult liver than a child's. The finding, published in the journal Science, offers a biological explanation for something clinicians have documented for years without being able to trace: why childhood cancer survivors face elevated risk of liver disease and new cancers decades after treatment ends.
The survival numbers belong in the same sentence, as a STAT News report on the liver findings made clear. Before platinum-based chemotherapy, only 20% to 30% of children with hepatoblastoma survived. Cisplatin pushed the five-year survival rate for localized disease above 90%. This is a study about the cost of a treatment that works, not a reason to question whether it should be used.
For families of childhood cancer survivors, the practical consequence is about follow-up rather than treatment decisions. The researchers argue the mutation burden supports long-term liver monitoring for children who received these drugs, a form of surveillance that is not currently standard for this specific risk.
A Mutation Signature Found Only in the Liver
The team analyzed 186 samples covering a range of tissues from nine children with liver cancer treated with cisplatin or carboplatin, and compared them against 77 samples from children treated with other drugs or not treated at all, as well as fetal liver tissue. The sequencing method, called NanoSeq, reads both strands of DNA independently, which allows mutations to be called from single DNA molecules rather than only those that have spread through a whole clone. A detailed account of the sequencing analysis describes how the comparison groups were assembled.
What emerged was a mutational pattern specific to the liver and absent from other tissues examined. That tissue specificity is the novel part. Platinum mutational signatures turned up widely across tissues, lifting mutation burdens in children to levels normally seen in adults, but the distinct liver signature had not been described before.
Anna Wenger of the University of Gothenburg and the Wellcome Sanger Institute, the study's first author, described the effect in terms of accelerated aging. "Chemotherapy causes healthy cells in children to age genetically," she said in Wenger's description of accelerated genetic aging, adding that treatment produced in a short period the amount of DNA damage that would normally accumulate over decades.
The analysis also found a wide diversity of mutations that change proteins, including some in blood with leukemia-associated potential. That observation connects to an established clinical reality, since therapy-related leukemia is a recognized complication of intensive chemotherapy for solid tumors in children.
Limits That Belong Beside the Headline
This is a small study. Nine children treated with platinum agents formed the core sample, which is a consequence of how rarely liver tissue becomes available for this kind of analysis. It does not make the result weak, but it does limit how far the findings generalize. Hepatoblastoma itself is rare.
More importantly, the study measured mutations, not outcomes. It did not follow these children forward to count how many developed liver disease or a second cancer. A higher mutation burden raises the statistical likelihood that a cancer-driving mutation lands somewhere consequential, but the paper does not establish how much individual risk that translates into, or when.
Writing in an accompanying Science perspective on liver aging, pediatric surgical oncologist Sanjeev A. Vasudevan and pediatric oncologist D. Williams Parsons said the findings "call for long-term monitoring of these children" to identify liver disease or new cancers early enough to intervene. Neither was involved in the research.
Nothing in the study changes current treatment protocols. Platinum agents remain the backbone of therapy for hepatoblastoma, and the researchers were explicit that equally effective alternatives do not exist. The known long-term effects of these drugs already include hearing loss and declining kidney function, both of which are actively monitored in survivorship care.
Questions Survivors and Parents Can Raise
Families of children currently in treatment should not read this as a reason to hesitate. The decision calculus has not shifted: untreated hepatoblastoma is usually fatal, and the drugs that changed that remain the drugs that changed that.
Adult survivors of childhood cancer are the group with something actionable here. Anyone treated with cisplatin or carboplatin as a child can ask whether their survivorship care plan includes liver monitoring, what their cumulative platinum dose was, and whether their treatment summary is documented somewhere they can access. Many survivors treated decades ago never received a written summary, and reconstructing it later is difficult.
Survivorship clinics at major pediatric centers typically follow guidelines from the Children's Oncology Group, which address hearing, kidney, and cardiac late effects. Liver surveillance specifically tied to mutational burden is not part of standard protocols, which is precisely what the study's authors are arguing should be reconsidered.
Wenger has said the longer-term aim is protective rather than diagnostic, and that a better understanding of how treatment affects healthy tissue could eventually lead to ways to shield the body from this damage. Sodium thiosulfate already exists as a protective agent used to reduce cisplatin-related hearing loss, which establishes that the concept is workable, though nothing comparable exists for liver mutagenesis.
What remains unknown is whether the mutation burden measured here predicts actual disease in these specific children, whether the liver signature appears at the same intensity across other cancers treated with platinum drugs, and whether any intervention can reduce it without blunting the anti-cancer effect. Those questions require following large survivor groups for years.
The immediate takeaway for households is narrow and useful. Treatment worked, the trade-off is now measurable, and the response being proposed is closer monitoring rather than different chemotherapy.
Key Questions Answered
Does this mean platinum chemotherapy should be avoided? No. It raised five-year survival for localized hepatoblastoma from roughly 20% to 30% up to more than 90%, and no equally effective alternative exists.
What did the study actually measure? Mutations in healthy liver tissue, blood, and other tissues from children treated with cisplatin or carboplatin, using an ultrasensitive sequencing method.
How many children were studied? The core analysis covered 186 samples from nine children treated with platinum agents, compared against 77 samples from children given other drugs or no treatment, plus fetal liver tissue.
Does it prove survivors will develop new cancers? No. It found a mutation burden that plausibly explains elevated risk but did not follow patients forward to count outcomes.
What should adult survivors do? Ask a survivorship clinic whether liver monitoring is included in their care plan and obtain a written treatment summary if they do not have one.
Is there a way to protect against this damage? Not yet for the liver. Sodium thiosulfate is used to reduce cisplatin-related hearing loss, showing protective agents are possible in principle.
Has treatment guidance changed? No. Current protocols stand, and the researchers are calling for longer follow-up rather than different chemotherapy.
